Introducing mavacamten▼: The first and only licensed cardiac myosin inhibitor for symptomatic NYHA class II and III obstructive hypertrophic cardiomyopathy (HCM)1,2
Mavacamten is a first-in-class non-invasive, selective, allosteric and reversible cardiac myosin inhibitor that targets the underlying pathophysiology of obstructive HCM.1,2 By reducing excess actin-myosin cross-bridge formation, mavacamten can help to normalise contractility, reduce dynamic LVOT obstruction and improve cardiac filling pressures in patients with obstructive HCM.1,2
